Why TC Biopharm (TCBP) Stock Is Down Over 60% Today
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Source: Benzinga
Stock Performance: TC Biopharm PLC shares have dropped 62% to 58 cents after the company announced its transition from Nasdaq to OTC markets due to delisting for not meeting the $1.00 minimum bid price requirement.
Company Focus and Appeal: The clinical-stage biotech firm specializes in allogeneic gamma-delta T-cell therapies for cancer and is currently appealing Nasdaq's decision to regain compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
